NCT04678921 - Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

November 21, 2022

Study Completion Date

November 21, 2022

Conditions

Solid TumorMetastatic CancerAdvanced Cancer

Interventions

DRUG

TJ210001

human anti-C5aR monoclonal antibody

Trial Locations (4)

Virginia Cancer Specialists, Fairfax

Horizon Oncology Center, Lafayette

University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora

Huntsman Cancer Institute, University of Utah, Salt Lake City